FDA Delays Approval Review for Exelixis' Zanzalintinib Combination Therapy for Metastatic Colorectal Cancer by 3 Months
Extension of PDUFA Review Deadline and Request for Data Supplement
The U.S. Food and Drug Administration (FDA) has postponed its decision on the combination therapy review of Exelixis' oral multi-tyrosine kinase inhibitor (TKI) zanzalintinib (XL092) and Roche's anti-PD-L1 immune checkpoint inhibitor Tecentriq (atezolizumab). The Prescription Drug User Fee Act (PDUFA) target date for the prescription drug applicant's fee has been adjusted by three months from December 3, 2026, to March 2027, requiring submission of the latest safety and efficacy data. This measure is not a complete failure or a Complete Response Letter (CRL), but rather an extension of the review period, indicating that authorities will closely verify long-term efficacy data.
Pros and Cons of the STELLAR-303 Phase 3 Trial and Subgroup Variables
The Phase 3 clinical trial (STELLAR-303) that served as the basis for this approval application directly compared the therapy with Bayer’s Stivarga (regorafenib) in patients with metastatic colorectal cancer (mCRC) who had failed prior treatments. In the Intention-to-Treat (ITT) population, the improvement in overall survival (OS), the primary endpoint, met statistical significance and raised high expectations. However, the failure to demonstrate improved survival in the subgroup of patients without liver metastasis emerged as a variable in the regulatory review process.
Wall Street Analysts' Optimism and Sustained Approval Odds
Professional Wall Street institutions, including William Blair and Leerink Partners, assess the risk of regulatory rejection as remaining very low. Given that robust survival benefit was demonstrated in the overall population regardless of liver metastasis, we believe the possibility of approval for a third-line (3L) indication remains valid. The fact that the FDA requested only an update of existing follow-up data rather than new clinical trials supports the view that this is merely a schedule postponement rather than a commercialization failure.
$4.5 Billion Pipeline Value and Portfolio Scalability
Ranlazartinib is Exelixis' key next-generation growth driver, defending the patent expiration of its lead product Cabometyx (cabozantinib). The market estimates that this drug will expand its indications to cover all urogenital and gastrointestinal cancers, generating $4.5 billion in annual sales in the U.S. alone by 2033. Despite this schedule delay, phase 3 pipeline readouts are pending, including STELLAR-311 for neuroendocrine tumors and STELLAR-304 for clear cell renal cell carcinoma.
Competitive Landscape in the 3rd-Line Treatment of Metastatic Colorectal Cancer
The 3rd-line treatment area for metastatic colorectal cancer is seeing intense market share competition among Takeda's Fruzaqla (fruquintinib) and Amgen's Lumakras (sotorasib). Patients awaiting a new option combining immunotherapy and anti-angiogenic therapy will face a 3-month delay in its introduction. However, if final approval is obtained, it possesses the potential to quickly establish itself as an innovative Standard of Care (SoC) that overcomes the limitations of existing single-target therapies.
The three-month extension of the FDA's PDUFA review deadline will temporarily delay market entry for this third-line treatment for metastatic colorectal cancer (mCRC), but the likelihood of final approval remains valid based on overall survival (OS) improvement data confirmed in the Phase 3 clinical trial (STELLAR-303). The commercialization timeline for the combination of immune checkpoint inhibitors and oral TKIs in the third-line colorectal cancer treatment market, dominated by Takeda's Fruzaqla and Bayer's Stivarga, has been delayed to March 2027, resulting in a slowdown in short-term momentum. However, Excelsior is sequentially launching phase 3 clinical trials for neuroendocrine tumors (STELLAR-311) and renal cell carcinoma (STELLAR-304), and its mid-to-long-term pipeline intrinsic value of $4.5 billion in potential U.S. sales by 2033 remains intact. In conclusion, investors and the industry should focus on subsequent Phase 3 pipeline readouts and the certainty of final approval in Q1 2027, rather than short-term stock price volatility, noting that the requirement is simply data supplementation without additional clinical trials.